2 min read
Scientists use AI to design new class of GPCR drugs called GEMs
Researchers designed new proteins called GEMs that target GPCRs, like the dopamine D1 receptor, as diverse allosteric modulators, offering a novel therapeutic strategy.
3 articles
Researchers designed new proteins called GEMs that target GPCRs, like the dopamine D1 receptor, as diverse allosteric modulators, offering a novel therapeutic strategy.
Isomorphic Labs, a Google DeepMind spin-off, has developed a proprietary AI model, IsoDDE, that predicts protein-drug interactions for drug discovery, but unlike AlphaFold, it is not being shared with the broader scientific community.
César de la Fuente uses AI to discover new antimicrobial peptides from diverse sources, including extinct species, to combat the growing threat of drug-resistant infections.